BenevolentAI Results Presentation Deck
"C
"With the world's attention on Al
applications that deliver real-world impact,
we are strongly positioned to capitalise on
this moment. With our substantial portfolio
of platform-generated drugs, our work with
big pharma and research collaborators,
and our continued investment in
state-of-the-art technology, we are showing
every day how Al can be used to unlock the
next wave of biopharma innovation."
Joanna Shields, CEO
Poised for growth: multiple
value inflection points expected
BEN-2293
• Top-line results of the Phase lla clinical trial expected
in Q1 2023
• Out-license in H2 2023 subject to results
BEN-8744
• Initiate the Phase I study in H1 2023
BEN-28010
Submit the CTA in H2 2023
2023
• Continued investment in state-of-the-art technology
• Aim to sign additional commercial collaboration
• Commence IND-enabling studies for at least one
additional asset
• Continue to progress pipeline assets to value
inflection points
Benevolent 23View entire presentation